Drug Profile


Alternative Names: EphB4-HSA; EphB4-Human Serum Albumin; Human Serum Albumin-EphB4 conjugate; Recombinant EphB4-HSA Fusion Protein; Vas 01

Latest Information Update: 08 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator VasGene Therapeutics
  • Developer National Cancer Institute (USA); University of Southern California; VasGene Therapeutics
  • Class Antineoplastics; Recombinant fusion proteins
  • Mechanism of Action EphB4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Bladder cancer; Chronic myelomonocytic leukaemia; Head and neck cancer; Kaposi's sarcoma; Myelodysplastic syndromes; Non-small cell lung cancer; Solid tumours
  • Phase I Prostate cancer; Renal cancer

Most Recent Events

  • 15 May 2017 Phase-II clinical trials in Myelodysplastic syndromes (Combination Therapy, Second-line therapy or greater, Late-stage disease, Metastatic disease) in USA (IV) (NCT03146871)
  • 20 Apr 2017 Phase-II clinical trials in Acute myeloid leukaemia (Combination Therapy) in USA (IV) (NCT03146871)
  • 20 Apr 2017 Phase-II clinical trials in Chronic Myelomonocytic leukaemia (Combination Therapy) in USA (IV) (NCT03146871)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top